Published in Tumori on October 31, 1994
Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med (1976) 9.68
Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med (1981) 7.53
Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer (1975) 2.52
Clinical evaluation of adriamycin, a new antitumour antibiotic. Br Med J (1969) 1.89
Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol (2000) 1.59
Radiofrequency thermal ablation of 69 lung neoplasms. J Chemother (2004) 1.58
A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer (1998) 1.55
A modified cell block technique for fine needle aspiration cytology. Acta Cytol (1995) 1.51
Phase I and preliminary phase II evaluation of adriamycin (NSC 123127). Cancer Res (1970) 1.50
Are surgical adjuvant trials altering the course of breast cancer? Semin Oncol (1978) 1.49
Phase II study of intensive CEV (carboplatin, epirubicin and VP-16) plus G-CSF (granulocyte-colony stimulating factor) in extensive small cell lung cancer. Eur J Cancer (1995) 1.42
Detection of haemagglutinin D222 polymorphisms in influenza A(H1N1)pdm09-infected patients by ultra-deep pyrosequencing. Clin Microbiol Infect (2012) 1.41
Laparoscopic colectomy for cancer and adequate lymphadenectomy: association between survival and number of lymph nodes. Surg Endosc (2006) 1.40
Rho GTPase control of protein kinase C-related protein kinase activation by 3-phosphoinositide-dependent protein kinase. J Biol Chem (2000) 1.33
cAMP-dependent phosphorylation of the nuclear encoded 18-kDa (IP) subunit of respiratory complex I and activation of the complex in serum-starved mouse fibroblast cultures. J Biol Chem (2000) 1.33
Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer. Cancer (1975) 1.31
Phosphoinositide 3-kinase is involved in the tumor-specific activation of human breast cancer cell Na(+)/H(+) exchange, motility, and invasion induced by serum deprivation. J Biol Chem (2000) 1.31
Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol (2005) 1.22
Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol (1978) 1.22
Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev (2010) 1.19
Acute renal failure during intermittent rifampicin therapy. Nephron (1973) 1.19
Multimodal treatment for locally advanced breast cancer. Result of chemotherapy-radiotherapy versus chemotherapy-surgery. Cancer Clin Trials (1981) 1.17
Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol (1999) 1.17
Response and survival in advanced breast cancer after two non-cross-resistant combinations. Br Med J (1976) 1.16
Prevention of endemic canine vector-borne diseases using imidacloprid 10% and permethrin 50% in young dogs: a longitudinal field study. Vet Parasitol (2010) 1.16
Molecular pathways and related target therapies in liver carcinoma. Curr Pharm Des (2007) 1.11
Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer (2000) 1.11
Inhibition of HIV type 1 BaL replication by MIP-1alpha, MIP-1beta, and RANTES in macrophages. AIDS Res Hum Retroviruses (1998) 1.10
Metastatic malignant melanoma of the gallbladder: a case report and review of the literature. Melanoma Res (2002) 1.09
Comparison of formalin, ethanol, and Histochoice fixation on the PCR amplification from paraffin-embedded breast cancer tissue. Eur J Clin Chem Clin Biochem (1997) 1.09
Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol (1997) 1.09
Cyclic adenosine monophosphate-dependent phosphorylation of mammalian mitochondrial proteins: enzyme and substrate characterization and functional role. Biochemistry (2001) 1.08
Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer (1989) 1.06
A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies. Crit Rev Oncol Hematol (2013) 1.05
Inflammatory cancer of the breast: analysis of 114 cases. J Surg Oncol (1981) 1.05
Multihance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol (1998) 1.05
Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer (2001) 1.02
Breast cancer: biological characteristics in postmenopausal type 2 diabetic women. Identification of therapeutic targets. Curr Drug Targets Immune Endocr Metabol Disord (2003) 1.01
HIV type 1 grown on interferon gamma-treated U937 cells shows selective increase in virion-associated intercellular adhesion molecule 1 and HLA-DR and enhanced infectivity for CD4-negative cells. AIDS Res Hum Retroviruses (1995) 1.01
The effect of fixation type on DNA extracted from paraffin-embedded tissue for PCR studies in dermatopathology. Dermatology (1997) 1.00
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. Ann Oncol (2008) 0.99
Jejunal adenocarcinoma in congenital heterotopic gastric mucosa. J Clin Gastroenterol (1988) 0.99
[Clinical trials with adriamycin in leukemia and solid tumors]. Tumori (1969) 0.98
Molecular mechanisms for the hepatic uptake of magnetic resonance imaging contrast agents. Biochem Biophys Res Commun (1999) 0.98
KEYnet: a keywords database for biosequences functional organization. Nucleic Acids Res (1999) 0.97
Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. Eur J Cancer (2001) 0.95
Cellular labeling with Gd(III) chelates: only high thermodynamic stabilities prevent the cells acting as 'sponges' of Gd3+ ions. Contrast Media Mol Imaging (2006) 0.94
Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer. Anticancer Res (2010) 0.94
Awareness of breast cancer genetics and interest in predictive genetic testing: a survey of a southern Italian population. Ann Oncol (2004) 0.93
Attitude towards genetic testing for breast cancer susceptibility: a comparison of affected and unaffected women. Eur J Cancer Care (Engl) (2009) 0.93
Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. Br J Cancer (2011) 0.92
Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group. J Clin Oncol (1999) 0.92
Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study. J Med Econ (2013) 0.92
p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis. Int J Cancer (1996) 0.92
Ovarian fibroma: our experience of 34 cases. Eur J Gynaecol Oncol (2003) 0.92
MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer. Anticancer Res (2007) 0.91
Genetic alterations in hereditary breast cancer. Ann Oncol (2004) 0.91
DNA flow cytometry, p53 levels and proliferative cell nuclear antigen in human colon dysplastic, precancerous and cancerous tissues. Anticancer Res (1998) 0.90
Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer. J Clin Oncol (2000) 0.90
Slow wave sleep dreaming. Sleep (1992) 0.90
Clinical trials with bleomycin in lymphomas and in solid tumors. Eur J Cancer (1972) 0.90
BRCAness: a deeper insight into basal-like breast tumors. Ann Oncol (2013) 0.90
Epithelial ovarian cancer: second and third line chemotherapy (review). Int J Oncol (2002) 0.89
Salvage treatment after r-interferon alpha-2a in advanced neuroendocrine tumors. Acta Oncol (1993) 0.89
A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice. Med Oncol (2013) 0.89
Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study. Ann Oncol (2007) 0.89
Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. J Urol (2000) 0.89
Ovarian bilateral cystic teratomas: diagnosis and therapy in a young woman. Clin Exp Obstet Gynecol (1990) 0.89
Effects of the human CD38 glycoprotein on the early stages of the HIV-1 replication cycle. FASEB J (1999) 0.89
Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group. J Clin Oncol (1999) 0.88
Serum 90K/MAC-2BP glycoprotein levels in hepatocellular carcinoma and cirrhosis. Anticancer Res (2000) 0.87
Abc protein transport of MRI contrast agents in canalicular rat liver plasma vesicles and yeast vacuoles. Biochem Biophys Res Commun (2001) 0.87
Adriamycin versus adriamycin plus melphalan in advanced ovarian carcinoma. Cancer Treat Rep (1977) 0.87
In vitro antitumour activity and cellular pharmacological properties of the platinum-iminoether complex trans-[PtCl2[E-HN=C(OMe)Me]2]. Int J Oncol (1999) 0.86
Mixed micelles containing lipophilic gadolinium complexes as MRA contrast agents. MAGMA (2001) 0.86
Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Br J Cancer (2005) 0.86
Heterogeneity of intratumour proliferative activity in primary breast cancer: biological and clinical aspects. Eur J Cancer (1995) 0.86
Apoptosis induced by denied adhesion to extracellular matrix (anoikis) in thyroid epithelial cells is p53 dependent but fails to correlate with modulation of p53 expression. FEBS Lett (1999) 0.85
Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells. Br J Cancer (2004) 0.85
Unusual response to second-line single-agent gemcitabine in locally advanced primary leiomyosarcoma of the lung: a case report. J Chemother (2003) 0.85
Update on capecitabine alone and in combination regimens in colorectal cancer patients. Cancer Treat Rev (2010) 0.85